Skip to main content
. 2021 Dec 8;37:33. doi: 10.1186/s42826-021-00110-3

Fig. 1.

Fig. 1

Experimental scheme for CT26 cell injection and cisplatin treatment in the three BALB/c substrains. After subcutaneous injection of CT26 cells, the syngeneic model was intraperitoneally administered varying doses of cisplatin (0.1, 1 and 5 mg/kg) once the tumor size reached 150 mm2